GBP1 and brain cancer: GBP1 has also been caught binding to TUBB3, an alternative microtubule subunit upregulated in taxane-resistant cancer cells, and PIM1, a potent promoter of cellular proliferation, in the formation of a cytoskeletal gateway of multi-drug treatment resistance (TXR) in ovarian, head-and-neck, breast, and brain cancers, implicating it as a key target in the fight against TXR+ disease and its associated mortality.